Trending Now
Editas Medicine Inc (NASDAQ:EDIT) Strikes Multi-Year Deal With Azzur Group For...
Editas Medicine Inc (NASDAQ:EDIT) recently announced that it signed a multi-year deal with Azzur Group, facilitating the production of pipeline treatments at current Good...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Free Money to Drive Gold Stocks in 2021? (KGC, GOLHF, NGD)
Here comes at least another $900 billion.
If Trump and Bernie get their way, it will be significantly more....
MAKE IT MODERN
LATEST REVIEWS
NRx Pharmaceuticals (NASDAQ: NRXP) Announce Initial Commercial ZYESAMI (Aviptadil) Formulation, Allowing...
NRx Pharmaceuticals (NASDAQ: NRXP) has announced the validation of the first commercial ZYESAMI (aviptadil) formulation for intravenous use, permitting high volume production.
NRx has increase...
MAKE IT MODERN
PERFORMANCE TRAINING
Alector Inc (NASDAQ: ALEC) Announced the Results of the Phase-2 INFRONT-2 Open-Label Study of...
Aelector Inc (NASDAQ: ALEC) is a clinical biotech corporation that recently announced promising results from its Phase-2 INFRONT-2 trial of ALOO1. The Alzheimer's Association International...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Announces Positive Findings From Its ILLUMINATE-B Phase 3 Study
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) recently published the data collected from its ILLUMINATE-B phase 3 clinical trial evaluating an investigative therapy called lumasiran.
Lumasiran is an...
Cardiff Oncology Inc. (NASDAQ: CRDF) Releases New Data On Onvansertib in KRAS-Mutated mCRC Treatment
Cardiff Oncology Inc. (NASDAQ: CRDF) has announced the latest data from its clinical program investigating the combination of onvansertib with the standard of care...
Crypto Stocks Shine as Risk Capital Returns (RIOT, AXXA, CAN)
Investors have been on a wild ride in recent days, with risk assets soaring, then diving, then soaring again. In Tuesday’s buying...
IVERIC bio Inc. (NASDAQ:ISEE) Reports Positive Results In 18-Month Zimura Study in Geographic Atrophy...
IVERIC bio Inc. (NASDAQ:ISEE) has announced encouraging 18-month results from its first third phase clinical study (OPH2003) of Zimura for geographic atrophy secondary to...
MAKE IT MODERN
